[HTML][HTML] Reimbursement of drugs for rare diseases through the public healthcare system in Canada: where are we now?
D Menon, D Clark, T Stafinski - Healthcare Policy, 2015 - ncbi.nlm.nih.gov
Introduction: Over the past 20 years, the number of therapies developed for rare diseases
has rapidly increased. Often, these therapies represent the only active treatment for …
has rapidly increased. Often, these therapies represent the only active treatment for …
[HTML][HTML] Factors influencing delays in patient access to new medicines in Canada: a retrospective study of reimbursement processes in public drug plans
S Salek, S Lussier Hoskyn, JR Johns, N Allen… - Frontiers in …, 2019 - frontiersin.org
Individuals who rely on public health payers to access new medicines can access fewer
innovative medicines and must wait longer in Canada compared to major markets around …
innovative medicines and must wait longer in Canada compared to major markets around …
Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study
N Allen, SR Walker, L Liberti, C Sehgal… - … Open Access Journal, 2016 - cmajopen.ca
Background: The CADTH Common Drug Review was established in 2002 to prepare
national health technology assessment reports to guide listing decisions for 18 participating …
national health technology assessment reports to guide listing decisions for 18 participating …
New public governance in health care: health technology assessment for Canadian pharmaceuticals
Abstract The New Public Governance (NPG) paradigm addresses problems of complex and
fragmented policy‐making. Health care is an increasingly complex policy area, and Canada …
fragmented policy‐making. Health care is an increasingly complex policy area, and Canada …
[HTML][HTML] An exploratory analysis of predictors of concordance between Canadian common drug review reimbursement recommendations and the subsequent …
Results: Recommendation–listing concordance was high. Positive references to cost and
clinical outcomes compared to placebo were statistically associated with concordance …
clinical outcomes compared to placebo were statistically associated with concordance …
[PDF][PDF] Confidential
S Salek - cmajopen.ca
Background: The CADTH Common Drug Review was established in 2002 to conduct a
national ealth Technology Assessment report to guide listing decisions for 18 participating …
national ealth Technology Assessment report to guide listing decisions for 18 participating …
Perspectives on the Common Drug Review Process at the Canadian Agency for Drugs and Technologies in Health
P Lefebvre, MH Lafeuille, S Tiggelaar - Decision Making in a World of …, 2017 - Springer
Abstract The Common Drug Review (CDR) is a federal review process that provides funding
and adoption recommendations to Canadian provinces and territories on non-oncological …
and adoption recommendations to Canadian provinces and territories on non-oncological …
Development and application of classification methodologies for comparing reimbursement decision-making processes for new medicines
N Allen - 2015 - orca.cardiff.ac.uk
Health Technology Assessment (HTA) considers the therapeutic effectiveness of a health
technology and may also evaluate cost-effectiveness. The aim of this study was to evaluate …
technology and may also evaluate cost-effectiveness. The aim of this study was to evaluate …